Toripalimab, an anti-PD-1 antibody, is being tested in a single-arm, clinical trial (phase II) named NCT04389073 in patients with metastatic, HER2-negative BC to see how well it works clinically when combined with metronomic VNR. This evidence concerns the gene ERBB2 and breast cancer.